Synthesis of N4-(substituted phenyl)-N4-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells
摘要:
A series of fourteen N-4-(substituted phenyl)-N-4-alkyl/clesalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines was synthesized as potential microtubule targeting agents. The synthesis involved a Fisher indole cyclization of 2-amino-6-hydrazinylpyrimidin-4(3H)-one with cyclohexanone, followed by oxidation, chlorination and displacement with appropriate anilines. Compounds 6, 14 and 15 had low nanomolar potency against MDA-MB-435 tumor cells and depolymerized microtubules. Compound 6 additionally had nanomolar GI(50) values against 57 of the NCI 60-tumor panel cell lines. Mechanistic studies showed that 6 inhibited tubulin polymerization and [H-3]colchicine binding to tubulin. The most potent compounds were all effective in cells expressing P-glycoprotein or the 0111 isotype of tubulin, which have been associated with clinical drug resistance. Modeling studies provided the potential interactions of 6, 14 and 15 within the colchicine site. (C) 2012 Elsevier Ltd. All rights reserved.
Synthesis of N4-(substituted phenyl)-N4-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells
摘要:
A series of fourteen N-4-(substituted phenyl)-N-4-alkyl/clesalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines was synthesized as potential microtubule targeting agents. The synthesis involved a Fisher indole cyclization of 2-amino-6-hydrazinylpyrimidin-4(3H)-one with cyclohexanone, followed by oxidation, chlorination and displacement with appropriate anilines. Compounds 6, 14 and 15 had low nanomolar potency against MDA-MB-435 tumor cells and depolymerized microtubules. Compound 6 additionally had nanomolar GI(50) values against 57 of the NCI 60-tumor panel cell lines. Mechanistic studies showed that 6 inhibited tubulin polymerization and [H-3]colchicine binding to tubulin. The most potent compounds were all effective in cells expressing P-glycoprotein or the 0111 isotype of tubulin, which have been associated with clinical drug resistance. Modeling studies provided the potential interactions of 6, 14 and 15 within the colchicine site. (C) 2012 Elsevier Ltd. All rights reserved.
Synthesis of potential inhibitors of GTP-cyclohydrolase I: an efficient synthesis of 8-substituted 7-deazaguanines
作者:Colin L. Gibson、Klaus Paulini、Colin J. Suckling
DOI:10.1039/a608297a
日期:——
A novel two step synthesis of 8-substituted 7-deazaguanines is
developed and involves the regioselective alkylation of pyrimidinones 1a
and 1b with nitrosoalkenes derived from α-halo oximes followed by
transoximation to give the 7-deazaguanines 6a–d in 41–65%
overall yield
TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF
申请人:Gangjee Aleem
公开号:US20090082374A1
公开(公告)日:2009-03-26
The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof
申请人:Gangjee Aleem
公开号:US20130096146A1
公开(公告)日:2013-04-18
The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
Tricyclic compounds having antimitotic and/or antitumor activity and method of use thereof
申请人:Duquesne University of the Holy Spirit
公开号:US10414777B2
公开(公告)日:2019-09-17
The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
本发明提供了三环化合物、其药学上可接受的盐、原药、溶液剂或水合物,它们具有抗有丝分裂活性、抗多种药物耐药性活性(例如 P 糖蛋白抑制)和抗肿瘤活性,可抑制紫杉醇敏感和耐药的肿瘤细胞。还提供了利用这些化合物治疗肿瘤细胞和抑制癌细胞有丝分裂的方法。
Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
申请人:Duquesne University of the Holy Spirit
公开号:US10464944B2
公开(公告)日:2019-11-05
The present invention provides tricyclic compounds, pharmaceutically acceptable salts, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.
本发明提供了具有抗有丝分裂活性、抗多药耐药性活性(例如 P 糖蛋白抑制)和抗肿瘤活性的三环化合物、其药学上可接受的盐、溶液或水合物,它们能抑制紫杉醇敏感和耐药的肿瘤细胞。还提供了利用这些化合物治疗肿瘤细胞和抑制癌细胞有丝分裂的方法。